

REMARKS

Claims 1 and 39-46, re-numbered as 1-9, have been allowed.

This amendment under 37 CFR 1.312 is being filed concurrently with payment of the issue fee. No amendments to the disclosure or to the claims are made herein. This amendment is filed only for clarification of a typographical error and requires no additional search or examination.

At page 2, item 2 of the Examiner's Amendment mailed on June 21, 2006, the Examiner made the following amendment:

II. In claim 39 line 3 after "SEQ ID NO:2" insert—which is linked to Type II diabetes—.

Applicants respectfully point out that claim 39 is drawn to SEQ ID NO:4 and not SEQ ID NO:2; see Response filed on November 28, 2005). Thus, the Examiner's amendment should read:


II. In claim 39 line 3 after "SEQ ID NO:4" insert—which is linked to Type II diabetes—.

Although the typographical error does not change the claim language, Applicants wish to clarify the prosecution record and avoid potential confusion upon printing of this patent.

CONCLUSION

Applicants respectfully request favorable consideration of the instant amendment followed with issuance of the above-referenced application as a US Patent.

Respectfully submitted,



Ferris H. Lander
Registration # 43,377

McHale & Slavin, P.A.
2855 PGA Boulevard
Palm Beach Gardens, FL 33410
(561) 625-6575 (Voice)
(561) 625-6572 (Fax)

\\Ns2\server\CLIENT FILES\2100-2199\2132 -Syn-X\2132_000110 - Protein Biopolymer
Markers\Amendments\2132_110_312_Amend_kfdw.wpd